•STERIS priced the 2033 bonds at a yield of 5.687% and a spread of 92 basis points, and the 2036 bonds at a yield of 5.894% and a spread of 102 basis points.
•The purchase price for Xodus Medical is about $2.1 billion in cash, with potential additional consideration of up to $150 million.
•STERIS expects to add about $2.0 billion of debt to finance the acquisition, following outstanding debt of about $1.9 billion on September 30, 2026.
•Sempra estimated the deal’s gross base price at about $9.99 billion.
•The consideration includes $4.65 billion in cash at closing, $4.14 billion through an interest-bearing instrument, and $1.20 billion in notes.
•The company estimated a pretax gain of between $2.80 billion and $3.30 billion and an after-tax gain of between $2.00 billion and $2.40 billion, before post-closing adjustments.
•ROC revenue in the third quarter was $8.0 million, up 50% year over year.
•Gross margin rose to 90% from 79% a year earlier.
•The potential value of the U.S. Department of Justice contract was $64.3 million over eight years, including approximately $7.4 million for the committed base period.
•VICI added a $500 million unsecured term loan to its credit agreement.
•The company expects to use $500 million to redeem part of notes with an aggregate principal amount of $729.5 million and an interest rate of 5.750% on November 19, 2026.
•Live Oak closed an offering of 4,000,000 Series B depositary shares on November 12, 2026.
•Each depositary share represents a 1/40 interest in a preferred share, with a stated fixed annual distribution rate of 8.750% and a liquidation value of $25.
•Net income attributable to common shareholders was $24.3 million, and diluted earnings per share were $0.52 in the third quarter of 2026.
